BUZZ-Citi initiates coverage on 89bio with 'buy' rating on potential for MASH therapy
** Brokerage Citi initiates coverage on 89bio ETNB.O with "buy" rating
** Brokerage sets PT at $25, representing a near triple upside to the stock's last close
** Citi remains optimistic about co's experimental drug, pegozafermin, for patients with a type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH)
** "If 89bio can replicate its early results of pegozafermin in larger trials and show a synergistic effect when used in combination of GLP-1s, pegozafermin could become a significant player in the MASH space", says Citi
** Eight of 9 brokerages rate the stock "buy" or higher, 1 "hold"; their median PT is $29.67, according to data compiled by LSEG
** Up to last close, ETNB has fallen 35.1% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available